Soc. Generale Call 240 AMGN 21.06.../ DE000SQ8SEJ7 /
23/05/2024 08:26:40 | Chg.-0.56 | Bid10:18:00 | Ask10:18:00 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
6.32EUR | -8.14% | 6.30 Bid Size: 2,000 |
- Ask Size: - |
Amgen Inc | 240.00 USD | 21/06/2024 | Call |
GlobeNewswire
22/05
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
21/05
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
21/05
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
15/05
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
14/05
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
14/05
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
13/05
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
09/05
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
08/05
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...